The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Fintel reports that on July 25, 2025, William Blair downgraded their outlook for Ameriprise Financial (NYSE:AMP) from ...

William Blair analysts lowered their rating on Ameriprise stock to Market Perform from Outperform Friday following the financial services firm’s second-quarter report.

This AI giant dominates the market, and despite its explosive growth, the stock might be cheaper than you think.

William Blair on Monday upgraded Stitch Fix (SFIX) shares to 'Outperform' from 'Market Perform,' sending the stock up nearly ...

Palantir Technologies Inc. (NASDAQ: PLTR) is one of the best 52-week high stocks to buy now. On July 21, the stock was a big ...

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

ICON lifts its 2025 revenue forecast, beats booking targets in Q2 and expands its share buyback plan as market conditions ...

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

A key driver of Tesla's profit is disappearing fast as the U.S. government changes policies on an environmental asset known ...

The William Blair venture that utilizes InvestCloud's cloud-based technology was created to give advisors access to a suite of proprietary software aimed at streamlining day-to-day operations and ...

He was preceded in death by sons William Blair III and Jordan Blair. Advertisement “He was a Renaissance man,” said Gregory Jordan, a nephew.